Moderna Inc is a biotechnology company focused on developing innovative messenger RNA (mRNA) therapeutics and vaccines for a wide array of diseases. Utilizing its proprietary mRNA technology platform, Moderna aims to harness the body's own cellular machinery to produce proteins that can help prevent or treat illnesses, including infectious diseases, cancer, and rare genetic disorders. The company gained significant attention for its development of an effective COVID-19 vaccine, but its pipeline also includes various other candidates in different stages of clinical development aimed at addressing unmet medical needs. Through its research and development efforts, Moderna seeks to transform the field of medicine and improve patient outcomes globally. Read More
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco...
Some large merger & acquisition deals that could shake up the consumer goods and the food distribution industry, plus deals in the healthcare industry.
CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010, its investigational seasonal influenza vaccine, and for mRESVIA® (mRNA-1345), its mRNA respiratory syncytial virus (RSV) vaccine, at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, Germany, on April 17-21, 2026.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...
The biotechnology sector witnessed a seismic shift this week as Roivant Sciences (Nasdaq: ROIV) and its subsidiary Immunovant (Nasdaq: IMVT) reported a series of clinical and regulatory updates that have fundamentally reshaped the competitive landscape for autoimmune treatments. As of April 2, 2026, Roivant has reached a multi-year valuation peak,
What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa...
As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the Cambridge-based biotechnology pioneer is mid-pivot into what CEO Stéphane Bancel describes as "Moderna 2.0." The company that once boasted a market capitalization exceeding $150 billion during the [...]
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
The American corporate engine has proven far more durable than even the most optimistic analysts predicted just a year ago. As of March 27, 2026, final results for the fourth quarter of 2025 have confirmed a blended earnings growth rate of 14.2% for the S&P 500. This milestone
As of March 25, 2026, the global economic landscape has shifted from the volatility of previous years into a phase of "tenuous resilience." Fueled by a significant rebound in international trade and a surge in high-tech manufacturing, U.S. equity markets have shattered previous records in the opening quarter of
As of March 25, 2026, the S&P 500 stands at a critical crossroads. After a historic three-year run that saw the benchmark index post double-digit gains in 2023, 2024, and a robust 17.9% in 2025, investors are left wondering if the "AI Supercycle" has finally run out of
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such a...
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
The biotech sector has found its new North Star in 2026. As of mid-March, Moderna Inc. (NASDAQ: MRNA) has shocked Wall Street with a staggering 83% year-to-date gain, catapulting it to the upper echelons of the S&P 500 performance charts. This rally marks a definitive end to the "post-pandemic
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...
In a watershed moment for the biotechnology sector, BioNTech SE (NASDAQ: BNTX) has reported its full-year 2025 financial results, signaling the definitive end of the COVID-19 vaccine gold rush and the beginning of a high-stakes pivot toward oncology. The German biotech pioneer recorded a net loss of €1.1 billion
